GLUEMonte Rosa Therapeutics, Inc.
$10.83+5.0% 1Y
$10.83
$9.3552 weeks$25.31
Is the business good?
How good a business is GLUE?
Monte Rosa Therapeutics, Inc. spent more than it took in: an operating loss of $182M on $29M of revenue, 12 months to Q2 2026.
$182M
Operating loss · on $29M of revenue · 12 months to Q2 2026
- Share count, year on year
- +23%
Share count, year on year · shareholders own a smaller slice than a year ago
Details›
- Operating margin12 months to Q2 2026
- −633%
- Net margin12 months to Q2 2026
- −561%
- Free cash flow margin
- −112%
- R&D as % of revenue
- 594%
- Revenue, trailing twelve months
- $29M
- Free cash flow, trailing twelve months
- −$32M
- Net income, trailing twelve months
- −$161M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.
On our screens:Most shorted stocks